Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.
Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. · 2011
Read Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. by Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3179347.txt.
Introduction
Ulrike Mödder and colleagues measured a bone-formation brake in the blood of nearly seven hundred adults in a 2011 paper in the Journal of Bone and Mineral Research. The protein, made by bone-embedded cells, blocks a key growth signal. Nothing was known about how its blood level varies with age, sex, or bone mass in people, so the team sampled a whole community age range.
Men carried clearly higher levels than women. Levels climbed steeply across life, more than doubling in women and rising several-fold in men. At any given amount of bone, older people carried more of the brake than younger people. The age rise may help explain why bone formation falters late in life, and the study gives the reference patterns needed before the protein can serve as a clinical marker.
Catalog record
| CREATOR | Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men By Ulrike I Mödder, Kelley A Hoey, Shreyasee Amin, Louise K McCready, Sara J Achenbach, B Lawrence Riggs, L Joseph Melton, Sundeep Khosla Published in: Journal of Bone and Mineral Research DOI: 10.1002/jbmr.217 ABSTRACT Sclerostin is a potent inhibitor of Wnt signaling and bone formation. However, there is currently no information on the relation of circulating sclerostin levels to age, gender, or bone mass in humans. Thus we measured serum sclerostin levels in a population-based sample of 362 women [123 premenopausal, 152 postmenopausal not on estrogen treatment (ET), and 87 postmenopausal on ET] and 318 men, aged 21 to 97 years. Sclerostin levels (mean ± SEM) were significantly higher in men than women (33.3 ± 1.0 pmol/L versus 23.7 ± 0.6 pmol/L, p < .001). In pre- and postmenopausal women not on ET combined (n = 275) as well as in men, sclerostin levels were positively associated with age (r = 0.52 and r = 0.64, respectively, p < .001 for both). Over life, serum sclerostin levels increased by 2.4- and 4.6-fold in the women and men, respectively. Moreover, for a given total-body bone mineral content, elderly subjects (age ≥ 60 years) had higher serum sclerostin levels than younger subjects (ages 20 to 39 years). Our data thus demonstrate that (1) men have higher serum sclerostin levels than women, (2) serum sclerostin levels increase markedly with age, and (3) compared with younger subjects, elderly individuals have higher serum sclerostin levels for a given amount of bone mass. Further studies are needed to define the cause of the age-related increase in serum sclerostin levels in humans as well as the potential role of this increase in mediating the known age-related impairment in bone formation. © 2011 American Society for Bone and Mineral Research. INTRODUCTION Considerable work over the past decade has established the Wnt/β-catenin signaling pathway as a major regulator of bone mass.(1,2) Activation of this pathway results in an expansion of osteoprogenitor cells as well as reduced apoptosis of mature osteoblasts, leading to increased bone formation and potentially marked increases in bone mass.(1,2) The effects of Wnt ligands on the canonical signaling pathway involving β-catenin signaling are mediated by binding of these ligands to a seven-transmembrane domain-spanning frizzled receptor and either of two coreceptors, low-density lipoprotein receptor–related proteins (LRP) 5 or 6.(1,2) Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass by binding to LRP5 and LRP6 to inhibit the canonical Wnt/β-catenin signaling pathway.(1,3–6) The biologic importance of sclerostin in humans is highlighted by sclerosteosis and van Buchem disease, two genetic diseases associated with markedly increased bone mass.(7–10) Sclerosteosis is caused by a mutation in the gene encoding sclerostin, SOST, that leads to improper splicing of the SOST mRNA,(7,8) whereas van Buchem disease is due to a deletion of an enhancer element downstream of the SOST gene.(9,10) In addition to these human diseases, mice with knockout of the Sost gene also have increased bone-formation rates at trabecular, endocortical, and periosteal surfaces, as well as increased bone mass.(11) Thus, given the compelling evidence for sclerostin as a major regulator of Wnt signaling and bone mass, an antisclerostin neutralizing antibody has been developed recently as a novel anabolic treatment for osteoporosis.(12) Despite growing understanding of the basic biology of Wnt signaling and its regulation by sclerostin, there are currently sparse data on assessment of circulating sclerostin levels in humans. Using an in-house Amgen immunoassay (Thousand Oaks, CA, USA), Mirza and colleagues(13) demonstrated that sclerostin could be measured in peripheral serum and was higher in 20 postmenopausal than in an equal number of premenopausal women. These investigators also found that in the postmenopausal women there were significant negative correlations between sclerostin levels and the free estrogen (E) index and parathyroid hormone (PTH) levels. In recent studies, we used a commercially available immunoassay (Biomedica, Vienna, Austria) to demonstrate that E treatment decreased circulating sclerostin levels in women and that selective elimination of E, but not testosterone (T), production in men resulted in increased serum sclerostin levels.(14) In addition, Gaudio and colleagues(15) have used the same immunoassay to demonstrate increased circulating sclerostin levels in long-term immobilized patients. Thus, given the availability of a validated immunoassay for sclerostin, we sought in this study to measure serum sclerostin levels in a population-based sample of women and men in order to define possible relations of sclerostin levels to age and gender, as well as bone mass, microstructure, sex steroid levels, and bone turnover markers. METHODS Study subjects We recruited subjects from an age-stratified random sample of Rochester, MN, residents who were selected using the medical records linkage of the Rochester Epidemiology Project.(16) This population is highly characteristic of the U.S. white population, but blacks and Asians are underrepresented.(17) The sample spanned ages from 21 to 97 years and included 362 women and 318 men. Reflecting the ethnic composition of the community, 98% of the subjects were white. There were 123 premenopausal women and 239 postmenopausal women; of the postmenopausal women, 87 were on some form of estrogen therapy (ET, defined as oral or transdermal E preparations with or without a progestin). All studies were approved by the Mayo Institutional Review Board, and written informed consent was obtained from all subjects prior to evaluation. Study protocol Subjects were evaluated at the outpatient Clinical Research Unit following an overnight fast. They consumed their habitual diet the day prior to study without any dietary restrictions. Following a blood draw, the subjects underwent the various imaging procedures described below. Total-body dual-energy X-ray absorptiometry (DXA) This study was designed originally to focus on volumetric quantitative computed tomographic (QCT) parameters and did not include site-specific DXA measures of the spine or hip. However, the subjects did have a total-body DXA performed (Prodigy, GE Medical Systems, Madison, WI, USA) using software Version 6.10.029. From this, we derived the total-body bone mineral content (TBBMC) and total-body bone mineral density (TBBMD). In addition, we were able to obtain the spine region areal BMD (aBMD) from the total-body scans. We have shown previously that such scans are equivalent to dedicated lumbar spine DXA measurements in women, with r = 0.92 and an error in predicting lumbar spine BMD of 6.5%.(18) Central QCT As described previously,(16,19) single-energy CT scans were made at the lumbar spine and proximal femur with a multidetector Light Speed QX-I Scanner (GE Medical Systems, Wakesha, WI, USA). Calibration standards scanned with the patient were used to convert CT numbers directly to equivalent volumetric BMD (vBMD) in mg/cm3.(20) To study age- and sex-specific structural changes in bone mineral distribution and structure, we developed software for the analysis of bone structure, geometry, and volumetric density from the CT images, specific details of which have been described previously.(19) To validate our image-processing algorithm, we made 10 scans of the European spine phantom, which is composed of hydroxyapatite.(21) The correlation between bone density results determined by our algorithm and that of the spine phantom was r = 0.998; using scans of L2 from the phantom over 10 days, vBMD was estimated to have a coefficient of variation (CV) of 0.7%. HRpQCT Details regarding the high-resolution peripheral quantitative computed